GM-CSF Inflammatory Mediator Therapy for Cognitive Impairment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods cannot accurately predict which individuals with Mild Cognitive Impairment (MCI) will progress to dementia, and there are no effective treatments to halt or reverse the cognitive decline associated with Alzheimer's disease.
Innovation Solution
Administering inflammatory mediators such as GM-CSF, which can cross the blood-brain barrier, to increase cognitive responses and exert neural protective effects, thereby decreasing the progression of cognitive impairment and reducing amyloid plaque deposition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used to predict dementia progression in MCI patients, then the diagnostic process is simple and non-invasive, but the prediction accuracy is insufficient and cannot reliably identify which individuals will progress to dementia
Solution Approach 1:
The patent introduces inflammatory mediators (such as GM-CSF, IL-6, TNF-alpha) as intermediary substances that can cross the blood-brain barrier and serve as biomarkers for predicting dementia progression. These mediators act as intermediaries between the diagnostic system and the pathological processes in the brain, providing measurable indicators of cognitive decline risk without requiring direct brain imaging or invasive procedures.
Solution Approach 2:
The patent replaces traditional mechanical/direct observation diagnostic methods with biochemical measurement systems. Instead of relying on behavioral observations or simple cognitive tests, the invention uses blood-based inflammatory mediator assays to detect and quantify pathological processes, substituting direct mechanical assessment with chemical/biological sensing.
2Reliability
If no treatment is administered to MCI patients, then the treatment approach is simple and avoids potential side effects, but cognitive decline progresses to dementia
Solution Approach 1:
The patent converts the harmful inflammatory response, which normally contributes to neurodegeneration, into a beneficial therapeutic target. By measuring and subsequently modulating inflammatory mediators that are naturally elevated in progressing MCI patients, the treatment transforms the pathological inflammatory process into a marker for targeted intervention, where the same inflammatory pathway is used to deliver protective effects.
Solution Approach 2:
The patent uses inflammatory mediators as intermediary targets for treatment. Rather than directly protecting neurons or clearing plaques, the therapy targets the inflammatory mediator pathway as an intermediate step, which then cascades into broader protective effects including reduced neurotoxicity, decreased plaque formation, and improved cognitive function.
3Reliability
If inflammatory mediators are administered to treat cognitive impairment, then cognitive function and neural protection are improved, but the treatment requires substances that can cross the blood-brain barrier which limits available options
Solution Approach 1:
The patent identifies inflammatory mediators with multiple functions that can address several pathological mechanisms simultaneously. For example, GM-CSF not only reduces amyloid plaque deposition but also enhances cognitive function and provides neuroprotection. This multi-functionality allows a single treatment agent to address multiple aspects of Alzheimer's pathology, compensating for the limited availability of blood-brain barrier-crossing compounds.
4Reliability
If amyloid plaque deposition is targeted for reduction, then the underlying pathology of Alzheimer's disease is addressed, but the process requires long-term treatment to achieve meaningful clinical benefit
Solution Approach 1:
The patent employs preliminary action by intervening in the inflammatory mediator pathway early in the disease process, before extensive irreversible neuronal damage occurs. By targeting inflammatory mediators such as GM-CSF and IL-6 at the MCI stage, the treatment prevents the cascade of events that lead to plaque formation and neurodegeneration, achieving pathology reversal before it becomes too advanced.
Solution Approach 2:
The patent implements continuous treatment through regular administration of inflammatory mediator modulators to maintain therapeutic levels in the blood and brain. This continuous action ensures sustained suppression of pathological inflammatory responses and ongoing reduction of amyloid plaque deposition, preventing disease progression over extended periods.
Data Source
AI summary
The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.